Valneva and Pfizer Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine , VLA15

Valneva SE a specialty vaccine company, and Pfizer Inc. announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

source https://www.pharmatutor.org/pharma-news/2020/valneva-and-pfizer-collaboration-to-co-develop-and-commercialize-lyme-disease-vaccine-vla15